NATR — NATURES SUNSHINE PRODUCTS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 275053 ·
Last close
$21.27
Market Cap
$374.03M
52W High
$28.00
52W Low
$19.43
ADV30
144,575
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 122,892,000 | 89,977,000 | 9,545,000 | 5,118,000 | 261,458,000 | 87,578,000 | 94,542,000 |
| Dec 2025 | 123,807,000 | 89,779,000 | 5,322,000 | 4,107,000 | 261,146,000 | 93,891,000 | 99,593,000 |
| Sep 2025 | 128,339,000 | 94,049,000 | 8,975,000 | 5,334,000 | 264,805,000 | 95,554,000 | 98,101,000 |
| Jun 2025 | 114,750,000 | 82,299,000 | 4,274,000 | 5,333,000 | 254,875,000 | 81,345,000 | 91,193,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$35,321,000
Investing CF
$-6,480,000
Financing CF
$-23,773,000
CapEx
$-6,480,000
Dividends Paid
—
Buybacks
$-16,309,000
EPS Diluted TTM
$1.06
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$76,928,000
Inventory
$68,312,000
Receivables
$8,602,000
ST Investments
—
EBIT TTM
$29,910,000
Pretax Income TTM
$29,812,000
Interest Exp TTM
$98,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$489,788,000
EBITDA
$41,685,000
Free Cash Flow
$23,175,500
Enterprise Value
$308,882,208
Total Cash
$87,578,000
Total Debt
$22,430,000
Shares Out
17,584,871
Trailing EPS
$1.10
Book Value
$9.50
ROE
12.4%
ROA
6.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 480,144,000 | 24,743,000 | 19,521,000 | 261,146,000 | 99,593,000 | — | 35,321,000 |
| Dec 2024 | 454,364,000 | 20,095,000 | 7,696,000 | 240,855,000 | 79,864,000 | — | 25,298,000 |
| Dec 2023 | 445,320,000 | 18,749,000 | 15,076,000 | 249,773,000 | 90,233,000 | — | 41,226,000 |
| Dec 2022 | 421,910,000 | 16,258,000 | -390,000 | 229,778,000 | 82,731,000 | — | 710,000 |
TTM Snapshot
Revenues TTM
$440,105,000
NetIncome TTM
$13,010,000
OpCashFlow TTM
$0
Assets (Latest)
$240,855,000
Forward EPS
$1.28
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.50 · spot: $21.27 · call volume: 34 · put volume: 7
Expected Move to 2026-11-20:
±$5.85
(27.50%) —
implied range
$15.42 –
$27.12
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | $375.25M | $6.24 | — |
| AKBA | Akebia Therapeutics, Inc. | $375.56M | $1.40 | — |
| PTCHF | PureTech Health plc | $388.74M | $1.60 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $393.14M | $0.37 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $397.83M | $6.98 | — |
News headlines (Yahoo Finance, 1h cache)
3 Russell 2000 Stocks with Open Questions
2026-07-10 14:31 · Yahoo
1 Small-Cap Stock to Target This Week and 2 That Underwhelm
2026-07-03 16:26 · Yahoo
Personal Care Stocks Q1 In Review: Nature's Sunshine (NASDAQ:NATR) Vs Peers
2026-07-01 18:17 · Yahoo
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 We Avoid
2026-06-30 09:45 · Yahoo
3 Cash-Heavy Stocks Walking a Fine Line
2026-06-25 08:57 · Yahoo
3 Reasons to Sell NATR and 1 Stock to Buy Instead
2026-06-24 13:04 · Yahoo
How The Story Around Nature’s Sunshine (NATR) Is Shifting After Q4 And New Analyst Targets
2026-06-08 15:10 · Yahoo
How The Nature’s Sunshine (NATR) Narrative Is Shifting With Q4 Beats And Digital Growth
2026-05-25 12:09 · Yahoo
Discovering US Undiscovered Gems in May 2026
2026-05-18 17:33 · Yahoo
NATR Q1 Deep Dive: Digital Channel Expansion and Margin Gains Shape Outlook
2026-05-11 22:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.